April 24st, 2016:
U-Protein Express acquires patent rights on mutated human surfactant protein D as broad anti-influenza therapeutic from the Utrecht University.
October 29st, 2015:
U-Protein Express joins European Commission’s Marie Curie Innovative Training Network Programme PolarNet.
March 31st, 2015:
U-Protein Express, Utrecht University and GenMab receive a NWO grant for the production of tumor markers and novel antibodies (Dutch).
June 23rd, 2014:
U-Protein Express starts collaboration with Utrecht University on the generation of nanobodies. These nanobodies or Llama VHH domains are generated against human receptors.
December 25th, 2012:
U-Protein Express receives US patent covering a method on protein sequencing using Lys-N. The press release can be found here.
November 1st, 2012:
Job position available at U-Protein Express BV for a laboratory scientist with experience in molecular biology, cell culture and protein purification. A detailed description can be found here (Dutch).
September 17th, 2012:
U-Protein Express BV announces that it has closed a non-exclusive license agreement with ImmunoPrecise Antibodies Ltd. for their proprietary r-PEx transient HEK293-based expression platform for the production of recombinant antibodies.
January 27th, 2012:
U-Protein Express BV, Crossbeta Biosciences and Good Biomarker Sciences join forces to develop Alzheimer’s disease biomarker with a grant from IPC-BioFarmind.
December 1st, 2011:
U-Protein Express BV acquires patent rights for protein sequencing by mass spectroscopy from the Utrecht University, The Netherlands. Download the press release.
May 24-26 2011:
Visit us at the Recombinant Antibodies Conference 2011 in Barcelona.
April 3-7 2011:
Read our advertisement for Lys-N at the Proteomic Forum, Berlin, page 34.
October 5-7 2010:
Visit us at Biotechnica, Hannover.
First publication for the use of recombinant Lys-N in Biochemistry.
June 7th, 2010:
Prof. Dr. Piet Gros receives Spinoza Prize.
May 29th, 2010:
ArGEN-X licenses r-PEx technology. Press release May 2010.